Edition:
United States

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

5,497JPY
20 Apr 2018
Change (% chg)

¥-18 (-0.33%)
Prev Close
¥5,515
Open
¥5,501
Day's High
¥5,533
Day's Low
¥5,467
Volume
1,269,800
Avg. Vol
1,353,472
52-wk High
¥6,465
52-wk Low
¥5,200

Chart for

About

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company, mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The Company mainly provides its products and services in Japan, Europe and North America markets.

Overall

Beta: 0.91
Market Cap(Mil.): ¥1,781,777.00
Shares Outstanding(Mil.): 324.14
Dividend: 38.00
Yield (%): 1.38

Financials

  4507.T Industry Sector
P/E (TTM): 18.52 31.01 33.60
EPS (TTM): 296.76 -- --
ROI: 15.92 13.60 13.19
ROE: 17.43 15.26 15.00

BRIEF- Shionogi completes retirement of treasury shares

* Says it completed retirement of 5 million shares (1.5 percent stake) of its common stock on March 12

Mar 12 2018

BRIEF-Shionogi Announces FDA NDA, EMA MAA Acceptances For Lusutrombopag

* SHIONOGI ANNOUNCES FDA NEW DRUG APPLICATION (NDA) AND EMA MARKETING AUTHORIZATION APPLICATION (MAA) ACCEPTANCES FOR LUSUTROMBOPAG (S-888711)

Feb 26 2018

BRIEF-R&I affirms Shionogi & Co Ltd's rating at "A+" and says stable outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

Dec 15 2017

BRIEF-Shionogi to repurchase shares and retire treasury shares

* Says it will repurchase up to 4.8 million shares, representing 1.5 percent of outstanding

Nov 27 2017

U.S. FDA approves first two-drug HIV regimen in win for GSK

The U.S. Food and Drug Administration has approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at lessening the side effect burden of current treatments that combine three or four medicines.

Nov 22 2017

UPDATE 2-U.S. FDA approves first two-drug HIV regimen in win for GSK

* Two-drug approach differentiates GSK from Gilead (Adds context on GSK drive to improve pharma sales)

Nov 22 2017

U.S. FDA approves first two-drug HIV regimen

NEW YORK, Nov 21 The U.S. Food and Drug Administration on Tuesday approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at easing the side effects for long-term patients who are on the standard treatment involving three or more drugs.

Nov 21 2017

BRIEF-UMN Pharma says business and capital alliance with Shionogi

* Says it signed business and capital alliance agreement with Shionogi & Co Ltd on Oct. 31

Oct 30 2017

Earnings vs. Estimates